Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer

Table 2

Plasma CAIX in breast cancer patients.

Patient population	Chemotherapy	Time points	CAIX, pg/mL
			Mean	Median	Range
LABC	Neoadjuvant paclitaxel (T) + sunitinib (S) × 12 weeks followed by anthracycline (AC) × 15 weeks	Baseline ()	34.0	26.0	0–155
		Following T + S ()	48.4	28.5	0–239
		Following AC ()	49.6	42.2	15–172
MBC	Irinotecan + etoposide or paclitaxel + immunomodulatory agent	Baseline ()	90.7	76.9	31.2–254.7
		Following 4–6 weeks of	90.7	74.3	27.2–224
		chemotherapy ()

LABC: locally advanced breast cancer; MBC: metastatic breast cancer.